Novo Nordisk is a major pharmaceutical company that set out to challenge diabetes on the other side of the world. Using a “triple bottom line” of being socially and environmentally responsible, as well as financially responsible, it set out to ensure that diabetes sufferers received the treatment they need.
Preview
Similar resources
Authors: Ivanova, Yulia; Laursen, Sheena, and Thon, Caroline
Publication year:
2016
Language: English (EN)
Level of knowledge: Introductory: aware of
Usage rights: CC BY NC SA
Unless otherwise stated, all materials created by the FOSTER consortium are licensed under a CREATIVE COMMONS
ATTRIBUTION 4.0 INTERNATIONAL LICENSE.
This project has received funding from the European Union’s Seventh Framework Programme for research,
technological development and demonstration under grant agreement no 612425.